Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 Cases (1993-2002)

Journal of the American Veterinary Medical Association

Volumn 226, Issue 11, 2005, Pages 1869-1880

  Weinkle, Tristan K ^a,b   Center, Sharon A ^a   Randolph, John F ^a   Warner, Karen L ^a   Barr, Stephen C ^a   Erb, Hollis N ^a  

^a Department of Obstetrics Gynecology   (United States)

^b South Carolina Veterinary Emergency Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BICARBONATE; BILIRUBIN; COMPLEMENT COMPONENT C3; CREATINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; D DIMER; DANAZOL; ERYTHROCYTE ANTIBODY; FIBRINOGEN; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; POTASSIUM; PROTEIN; PROTHROMBIN; THROMBOPLASTIN; VINCRISTINE;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BICARBONATE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; COOMBS TEST; CREATININE BLOOD LEVEL; DOG DISEASE; ERYTHROCYTE DISORDER; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEMOLYTIC ANEMIA; IMAGING; IMMUNE MEDIATED INJURY; INFECTION; KAPLAN MEIER METHOD; LABORATORY TEST; LENGTH OF STAY; LOW DRUG DOSE; MALE; MORTALITY; NEOPLASM; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; POTASSIUM BLOOD LEVEL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SEX RATIO; STATISTICAL ANALYSIS; SURVIVAL RATE; VACCINATION; VETERINARY MEDICINE;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ASPIRIN; AZATHIOPRINE; BREEDING; DOG DISEASES; DOGS; FEMALE; GLUCOCORTICOIDS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE;

ANIMALIA; CANIS FAMILIARIS;

EID: 19744376787     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2005.226.1869     Document Type: Article

References (47)

1. Klag AR, Giger U, Shofer FS. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med Assoc 1993;202:783-788.
2. Duval D, Giger U. Vaccine-associated immune-mediated hemolytic anemia in the dog. J Vet Intern Med 1996;10:290-295.
3. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999;35:384-391.
4. Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. J Vet Intern Med 2002;16: 504-509.
5. Grundy SA, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc 2001;218:543-546.
6. Bennett D, Finnen SL, Nash AS, et al. Primary autoimmune haemolytic anaemia in the dog. Vet Rec 1981;109:150-153.
7. Mason N, Duval D, Shofer FS, et al. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune-mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med 2003;17:206-212.
8. Jackson ML, Kruth SA. Immune-mediated hemolytic anemia and thrombocytopenia in the dog: a retrospective study of 55 cases diagnosed from 1969 though 1983 at the Western College of Veterinary Medicine. Can Vet J 1985;26:245-250.
9. Burgess K, Moore A, Rand W, et al. Treatment of immune-mediated hemolytic anemia in dogs with cyclophospliamide. J Vet Intern Med 2000;14:456-462.
10. Kellerman DL, Bruyette DS. Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. J Vet Intern Med 1997;11:327-332.
11. Miller E. The use of cytotoxic agents in the treatment of immune-mediated diseases of dogs and cats. Semin Vet Med Surg (Small Anim) 1997;12:157-160.
12. Miller E. The use of danazol in the therapy of immune-mediated disease of dogs. Semin Vet Med Surg (Small Anim) 1997;12:167-169.
13. Vaden SL. Cyclosporine and tacrolimus. Semin Vet Med Surg (Small Anim) 1997;12:161-166.
14. Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of the dog that are unresponsive to conventional therapy. Transplant Proc 1998;30:4143-4148.
15. Klein MK, Dow SW, Rosychuck RAW. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J Am Vet Med Assoc 1989;195:246-250.
16. McManus PM, Craig LE. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). J Am Vet Med Assoc 2001;218:1308-1313.
17. Mischke RH, Schüttert C, Grebe SI. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res 2001;62:1887-1891.
18. Keith JC, Rawlings CA, Schaub RG. Pulmonary thromboembolism during therapy of dirofilariasis with thiacetarsamide: modification with aspirin or prednisone. Am J Vet Res 1983;44:1278-1283.
19. Smith SA, Tobias AH, Jacob KA, et al. Arterial thomboembolism in cats: acute crisis in 127 cases (1992-2001) and long term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003;17:73-83.
20. Pulmonary embolism prevention trial collaborative group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet 2000;35:1295-1302.
21. Robertson AJ, Nargund V, Gray DWR, et al. Low dose aspirin as prophylaxis against renal vein thrombosis in renal transplant recipients. Nephrol Dial Transplant 2000;15:1865-1868.
22. Patrono C. Aspirin: new cardiovascular uses for an old drug. Am J Med 2001;110:62S-65S.
23. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346:1468-1474.
24. Spencer FA, Santopinto JJ, Gore JM, et al. Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (the global registry of acute coronary events [GRACE]). Am J Cardiol 2002;90:1056-1061.
25. Wilkerson MJ, Davis E, Shuman W, et al. Isotype-specific antibodies in horses and dogs with immune-mediated hemolytic anemia. J Vet Intern Med 2000;I4:190-196.
26. Graça-Souza AV, Arruda MAB, de Freitas MS, et al. Neutrophil activation by heme: implications for inflammatory processes. Blood 2002;99:4160-4165.
27. Mazzaferro EM, Rudloff E, Kirby R. The role of albumin replacement in the critically ill veterinary patient. J Vet Emerg Crit Care 2002;12:113-124.
28. Margarson MP, Soni N. Serum albumin: touchstone or totem? Anaesthesia 1998;53:789-803.
29. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000;85:599-610.
30. Franch-Arcas G. The meaning of hypoalbuminemia in clinical practice. Clin Nutr 2001;20:265-269.
31. Gennari JF. Hypokalemia. N Engl J Med 1998:339:451-458.
32. Cohn JN, Kowey PR, Whelton PK, et al. New guidelines for potassium replacement in clinical practice. Arch Intern Med 2000; 160:2429-2436.
33. Whang R, Sims G. Magnesium and potassium supplementation in the prevention of diabetic vascular disease. Med Hypotheses 2000;55:263-265.
34. Wyss M, Kaddurah-Daouk R. Creatine and creatine metabolism. Physiol Rev 2000;80:1107-1213.
35. Weiss DJ. Primary pure red cell aplasia in clogs: 13 cases (1996-2000). J Am Vet Med Assoc 2002;221:93-95.
36. Kerr R, Rawlinson PSM, Cachia PG. Direct antiglobulin test negative, non-spherocytic autoimmune haemolytic anaemia. Clin Lab Haem 2000;22:365-367.
37. Beale KM. Azathioprine for treatment of immune-mediated disease of dogs and cats. J Am Vet Med Assoc 1988;192:1316-1318.
38. Miller E. Immunosuppression-an overview. Semin Vet Med Surg (Small Anim) 1997;12:144-149.
39. Ogilvie GK, Felsburg PJ, Harris CW. Short-term effect of cyclophosphamide and azathioprine on selected aspects of canine blastogenic response. Vet Immunol Immunopathol 1988;18:119-127.
40. Rinkardt NE, Kruth SA, Kaushik A. The effects of prednisone and azathioprine on circulating immunoglobulin levels and lymphocyte subpopulations in normal dogs. Can Vet J 1999;63:18-24.
41. Rinkardt NE, Kruth SA. Azathioprine-induced bone marrow toxicity in four dogs. Can Vet J 1996;37:612-613.
42. Scott-Moncrieff JC, Treadwell NG, McCullough SM, et al. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001;37:220-227.
43. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-589.
44. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
45. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-356.
46. Hofman WF, Fravel J, Ehrhart IC. Effect of aspirin on vascular tone and reactivity to vasoactive amines in the dog lung. Res Commun Chem Pathol Pharmacol 1992;78:47-56.
47. Capurro NL, Lipson LC, Bonow RO, et al. Relative effects of aspirin on platelet aggregation and prostaglandin-mediated coronary vasodilation in the dog. Circulation 1980;62:1221-1227.